MOORESTOWN, N.J. & NEW YORK–(BUSINESS WIRE)–EmblemHealth, New York’s leading health benefits and wellness company, and Tabula Rasa HealthCare, a family of companies devoted to leveraging technology to improve healthcare, announced the launch of a new Medication Therapy Management (MTM) pilot program.

Read on original publication

Medicare’s Part D Medication Therapy Management Program (MTMP) requires Part D sponsors, such as EmblemHealth, to ensure optimal therapeutic outcomes for targeted beneficiaries through improved medication use. The pilot program, entitled MTM+, or MTM Plus, is a proof of concept for enhanced MTM interventions particularly focused on medication safety for the most frail, elderly beneficiaries.

“Adverse drug events are ubiquitous; they are the 5th leading cause of death in the country,” said Tabula Rasa HealthCare CEO Calvin H. Knowlton, BscPharm, MDiv, PhD. “Working with EmblemHealth, we are looking to improve the prescribing process, increase medication safety, and reduce adverse drug events and hospitalizations.”

CareVentions, a subsidiary of Tabula Rasa HealthCare, will train EmblemHealth’s MTM pharmacists on the use of MedWise Advisor™, a proprietary tool that plots an individual’s entire medication regimen against various extrinsic and intrinsic medication safety factors. MedWise Advisor provides the MTM pharmacists with a Medication Risk Mitigation Matrix™ that the pharmacists will use when making recommendations to EmblemHealth’s beneficiaries and prescribers.